Welcome to our dedicated page for ASYMCHEM LABORATORIES TIANJIN news (Ticker: ASLTY), a resource for investors and traders seeking the latest updates and insights on ASYMCHEM LABORATORIES TIANJIN stock.
Asymchem Laboratories (Tianjin) reports news about its CDMO operations, site network, client manufacturing programs, and expansion of development and manufacturing capabilities. Recurring updates cover early-stage R&D services at Asymchem Boston, biologics capacity through AsymBio, and the integration of process development, pilot-scale production, and commercial manufacturing across small molecules, peptides, oligonucleotides, and biologics.
Company announcements also describe client production campaigns, GMP active pharmaceutical ingredient work, Shanghai biologics manufacturing assets, and specialized equipment such as single-use bioreactors, conjugation reactors, automated filling systems, and lyophilization capacity.
AsymBio (ASLTY), a biologics-focused CDMO under Asymchem Group, unveiled its Conjugation Toolbox platform to support customized, scalable process development for next-generation bioconjugates, including ADCs.
The toolbox spans random and site-specific conjugation, enables IND-enabling process development in about 2–3 months, and supports efficient tech transfer to GMP manufacturing.
AsymBio (ASLTY) announced its Fengxian commercial manufacturing site in Shanghai is now operational, completing a three-site Shanghai "Golden Triangle" with Zhangjiang and Jinshan. The network delivers end-to-end biologics CDMO capabilities from early R&D to large-scale commercial manufacturing.
The Dual Sites + One Center model links technology, pilot-scale, and commercial production and integrates Tianjin payload–linker resources to support antibody, protein, ADC, and NDC programs with specified single-use bioreactors and conjugation reactors.
Asymchem Laboratories has opened a new research and development site in Woburn, Massachusetts, named Asymchem Boston, to enhance its global operations. This facility will focus on early-stage R&D services, including chemical process development and formulation studies for small molecules, peptides, and oligonucleotides. Currently operational with 6,000 sqft of lab space, expansion plans are set for 2023 to include a kilo-lab and additional support capabilities. Asymchem aims to better serve biotech clients and connect with manufacturing sites in China.
Asymchem and AUM Biosciences have successfully completed their first GMP production campaign of AUM601, a selective oral inhibitor targeting TRK for rare cancers. This collaboration led to 10 kg of GMP bulk drug substance for Phase II trials, showcasing AUM601's potent anti-tumor activities. Both companies emphasize commitment to quality in drug development, with CEO Vishal Doshi highlighting improved yield and quality through innovative manufacturing processes. This initiative aims to address significant oncology needs globally.